We actively communicate on our business, services and technical capabilities. Use the resources on this page to browse through recent news, to subscribe to our news services or to meet us at one of our forthcoming events.
PolyPeptide signs significant commercial agreement
19 Dec 2022 - Baar, 19 December 2022 – PolyPeptide Group AG (SIX: PPGN), a focused global CDMO for peptide- and oligonucleotide-based active pharmaceutical ingredients, today announced the signing of a […]
Read morePolyPeptide provides market update
2 Dec 2022 - Baar, 2 December 2022 – PolyPeptide Group AG (SIX: PPGN), a focused global CDMO for peptide- and oligonucleotide-based active pharmaceutical ingredients, today provided a market update. […]
Read moreFluoGuide reaches milestone with FG001 for phase III clinical supply
9 Nov 2022 - “We are thankful for the opportunity to work with FluoGuide on the highly innovative FG001 project and congratulate the whole team for reaching this milestone.”
Read moreFrom 10 grams to several hundred – A case study in peptide GMP process development
17 Oct 2022 - Presentation from TIDES digital week, September 2022, by Niall McLoughlin, PhD, Development Project Chemist at PolyPeptide Group.[…]
Read moreGreen Chemistry Articles of Interest to the Pharmaceutical Industry
22 Sep 2022 - The American Chemical Society Green Chemistry Institute Pharmaceutical Roundtable (ACSGCI PR) promotes the use of green and sustainable chemistry in the pharma industry and beyond. As a part of this initiative, reviews covering Green Chemistry articles of interest from a pharmaceutical perspective are periodically disclosed.[…]
Read morePolyPeptide with encouraging progress within custom projects pipeline – however with lower profitability in the first half of 2022
19 Aug 2022 - PolyPeptide Group AG (SIX: PPGN), a focused global CDMO for peptide- and oligo-nucleotide-based active pharmaceutical ingredients, today announced its detailed results for the first half of […]
Read morePolyPeptide provides market update
12 Jul 2022 - The EBITDA margin for the first half of 2022 is expected to be around 20% of revenue. Media Release – ad hoc announcement pursuant to Art. […]
Read morePolyPeptide wins Malmö Life Science Business Award
28 Jun 2022 - Malmö, 21 June 2022 We are proud of our site in Malmö, Sweden, for winning the Life Science Business Award of the city (Malmö Näringslivspris Life […]
Read moreMonika Casanova joining PolyPeptide as CHRO and member of the PMC
9 May 2022 - With 19 years of HR experience, the native German most recently worked as head of global HR for a building materials company.
Read more